{"title":"CD8+ T 细胞是多柔比星癌症疗法与心力衰竭风险之间的缺失环节","authors":"Susanne Sattler, Senka Ljubojevic-Holzer","doi":"10.1038/s44161-024-00513-0","DOIUrl":null,"url":null,"abstract":"Doxorubicin treatment is a mainstay of cancer therapy but causes potent cardiotoxicity that exposes cancer survivors to the risk of heart failure. A study now identifies CD8+ T cells of the adaptive immune system as major culprits in the development of doxorubicin-induced cardiomyopathy and heart failure.","PeriodicalId":74245,"journal":{"name":"Nature cardiovascular research","volume":"3 8","pages":"890-892"},"PeriodicalIF":9.4000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CD8+ T cells as the missing link between doxorubicin cancer therapy and heart failure risk\",\"authors\":\"Susanne Sattler, Senka Ljubojevic-Holzer\",\"doi\":\"10.1038/s44161-024-00513-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Doxorubicin treatment is a mainstay of cancer therapy but causes potent cardiotoxicity that exposes cancer survivors to the risk of heart failure. A study now identifies CD8+ T cells of the adaptive immune system as major culprits in the development of doxorubicin-induced cardiomyopathy and heart failure.\",\"PeriodicalId\":74245,\"journal\":{\"name\":\"Nature cardiovascular research\",\"volume\":\"3 8\",\"pages\":\"890-892\"},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2024-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature cardiovascular research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s44161-024-00513-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cardiovascular research","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44161-024-00513-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
多柔比星治疗是癌症治疗的主要方法，但会引起强烈的心脏毒性，使癌症幸存者面临心力衰竭的风险。现在的一项研究发现，适应性免疫系统的 CD8+ T 细胞是导致多柔比星诱发心肌病和心力衰竭的罪魁祸首。
CD8+ T cells as the missing link between doxorubicin cancer therapy and heart failure risk
Doxorubicin treatment is a mainstay of cancer therapy but causes potent cardiotoxicity that exposes cancer survivors to the risk of heart failure. A study now identifies CD8+ T cells of the adaptive immune system as major culprits in the development of doxorubicin-induced cardiomyopathy and heart failure.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
